NAC Trial for Anosmia

Completed · Early Phase 1

Conditions studied: Anosmia

In brief

The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evidence that the medication may promote nerve recovery (help nerves work better after they are damaged). Since anosmia involves nerve problems, we believe the nasal spray may help treat anosmia. The medication has been in use for many years for other conditions, without safety problems.

Key facts

Study ID

NCT02481609

Run by

University of Miami

People needed

29

Starts

2014-07-01

Expected to finish

2017-12-01

Last updated by the study team

2018-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults at least 18 years of age with documented microsmia or anosmia by University of Pennsylvania Smell Identification Test.
• patients must have no evidence of active sinonasal disease by nasal endoscopy or CT or MRI
• negative CT or MRI

You may not qualify if…

• adults unable to consent
• individuals who are not yet adults (infants, children, teenagers)
• pregnant women, prisoners, employees or subordinates,
• patients with known sensitivity to NAC or severe asthma
• patients with sinus or central disease on CT or MRI imaging.

Where it is running

• University of Miami, Miller School of Medicine, Clinical Research Building — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.